Report: Generics, biologics led the way in 2006

May 21, 2007

Biotech and unbranded generics growth outpaced nonbiotech brands and total market in 2006, with generics continuing to gain traction, according to an IMS Health report.

Biotech and unbranded generics growth outpaced nonbiotech brands and total market in 2006, with generics continuing to gain traction, according to an IMS Health report. Unbranded generics grew at 22.4% during the year (U.S. sales dollar growth), while biotech grew at a rate of 19.8%. Total market growth was 8.3%. The report also showed that seven of the top 10 launches in 2006 were generics, with clopidogrel bisulfate (Apotex) leading the way. In the same way, generic companies dominated the top 10 firms in total Rxs in 2006. The report also stated that U.S. biotech products are currently targeting cancer and supportive cancer treatments. "The U.S prescription market is strong and generics and biologics continue to lead the way," said Doug Long, VP of industry relations for IMS, who presented the report at the recent NCPDP Conference in Scottsdale, Ariz. "And pharmacy has a big role in the future."

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.